Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis. Issue 1 (16th December 2022)
- Record Type:
- Journal Article
- Title:
- Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis. Issue 1 (16th December 2022)
- Main Title:
- Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis
- Authors:
- Verde, Federico
Milone, Ilaria
Maranzano, Alessio
Colombo, Eleonora
Torre, Silvia
Solca, Federica
Doretti, Alberto
Gentile, Francesco
Manini, Arianna
Bonetti, Ruggero
Peverelli, Silvia
Messina, Stefano
Maderna, Luca
Morelli, Claudia
Poletti, Barbara
Ratti, Antonia
Silani, Vincenzo
Ticozzi, Nicola - Abstract:
- Abstract: Objective: To compare serum levels of the astrocyte biomarker glial fibrillary acidic protein (GFAP) in patients with amyotrophic lateral sclerosis (ALS) and neurologically healthy controls and to analyze the relations between serum GFAP (sGFAP) and phenotype in ALS. Methods: We studied 114 ALS patients and 38 controls. sGFAP was quantified with single molecule array (Simoa) technology. Results: In both ALS patients and controls, sGFAP moderately correlated with age. ALS patients had higher sGFAP levels compared to controls, but this yielded a weak discriminative performance (AUC = 0.6198). In ALS, sGFAP was not associated with most of the motor phenotypic features, including site of onset, functional status, disease progression rate, disease stage, and indices of upper (UMN) and lower motor neuron (LMN) impairment. However, sGFAP negatively correlated with cognitive scores regarding ALS‐nonspecific functions, particularly memory ( r = −0.2082) and tended to be higher in ALS patients with eye movement abnormalities ( p = 0.0628). sGFAP also correlated with polysomnographic indices of oxygen desaturation (ODI; r = 0.2639) and apnea‐hypopnea (AHI; r = 0.2858). In a multivariate analysis, sGFAP was negatively associated with survival (HR = 1.005). Relevantly, we found a negative correlation between sGFAP and estimated glomerular filtration rate (eGFR; r = −0.3500). Interpretation: Our work provides neurochemical evidence of astrocyte involvement in ALSAbstract: Objective: To compare serum levels of the astrocyte biomarker glial fibrillary acidic protein (GFAP) in patients with amyotrophic lateral sclerosis (ALS) and neurologically healthy controls and to analyze the relations between serum GFAP (sGFAP) and phenotype in ALS. Methods: We studied 114 ALS patients and 38 controls. sGFAP was quantified with single molecule array (Simoa) technology. Results: In both ALS patients and controls, sGFAP moderately correlated with age. ALS patients had higher sGFAP levels compared to controls, but this yielded a weak discriminative performance (AUC = 0.6198). In ALS, sGFAP was not associated with most of the motor phenotypic features, including site of onset, functional status, disease progression rate, disease stage, and indices of upper (UMN) and lower motor neuron (LMN) impairment. However, sGFAP negatively correlated with cognitive scores regarding ALS‐nonspecific functions, particularly memory ( r = −0.2082) and tended to be higher in ALS patients with eye movement abnormalities ( p = 0.0628). sGFAP also correlated with polysomnographic indices of oxygen desaturation (ODI; r = 0.2639) and apnea‐hypopnea (AHI; r = 0.2858). In a multivariate analysis, sGFAP was negatively associated with survival (HR = 1.005). Relevantly, we found a negative correlation between sGFAP and estimated glomerular filtration rate (eGFR; r = −0.3500). Interpretation: Our work provides neurochemical evidence of astrocyte involvement in ALS pathophysiology and particularly in the development of extra‐motor manifestations (namely, cognitive – memory – impairment) and respiratory dysfunction. The negative correlation between sGFAP and eGFR has practical relevance and should not be disregarded in future investigations. … (more)
- Is Part Of:
- Annals of clinical and translational neurology. Volume 10:Issue 1(2023)
- Journal:
- Annals of clinical and translational neurology
- Issue:
- Volume 10:Issue 1(2023)
- Issue Display:
- Volume 10, Issue 1 (2023)
- Year:
- 2023
- Volume:
- 10
- Issue:
- 1
- Issue Sort Value:
- 2023-0010-0001-0000
- Page Start:
- 118
- Page End:
- 129
- Publication Date:
- 2022-12-16
- Subjects:
- Nervous system -- Diseases -- Periodicals
Neurology -- Periodicals
616.8005 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/acn3.51708 ↗
- Languages:
- English
- ISSNs:
- 2328-9503
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25182.xml